TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05735184: Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acut

Sponsor: Kura Oncology, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 420 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$7,100,016

Rescue Site Savings

+$4,680,984

Unlock Full NCT05735184 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05735184 Rescue Dossier →